Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: This study investigated the influence of obesity on the clinical course and effect of gonadotropin-releasing hormone analog (GnRHa) treatment in girls with central precocious puberty (CPP). Methods: Medical records of 182 girls with CPP treated with GnRHa were reviewed. They were divided into 2 groups: normal weight (n=108) and overweight/obesity (n=74). Chronological age (CA), bone age (BA), difference between BA and CA (BA–CA), standard deviation score (SDS) of height, body mass index (BMI), predicted adult height (PAH), and laboratory findings were compared at baseline, after 1 year, and at the end of GnRHa treatment in both groups. Results: Mean BMI SDS at baseline was 0.08±0.60 in the normal weight group and 1.55±0.36 in the overweight/obesity group. Initial CA, BA, midparental height, and PAH were similar between the 2 groups. BA–CA after treatment was significantly decreased compared to baseline in both groups (P<0.001). Between the 2 groups, a decrease in BA–CA during treatment showed no significant difference. PAH at the end of treatment was significantly increased compared to baseline in both groups (P<0.001). PAH at the end of treatment in the overweight/obesity group (159.88±3.41 cm) was similar to that of the normal weight group (159.19±3.25 cm). Comparing the 2 groups according to change in BMI after treatment, there were no differences in ΔPAH, ΔBA–CA, and Δheight SDS for BA. Conclusion: GnRHa treatment in obese girls with CPP improved the height outcome and had similar results in normal weight CPP girls. Obesity might not affect the efficacy of GnRHa in girls with CPP.
Abstract
Purpose: This study investigated the influence of obesity on the clinical course and effect of gonadotropin-releasing hormone analog (GnRHa) treatment in girls with central precocious puberty (CPP). Methods: Medical records of 182 girls with CPP treated with GnRHa were reviewed. They were divided into 2 groups: normal weight (n=108) and overweight/obesity (n=74). Chronological age (CA), bone age (BA), difference between BA and CA (BA–CA), standard deviation score (SDS) of height, body mass index (BMI), predicted adult height (PAH), and laboratory findings were compared at baseline, after 1 year, and at the end of GnRHa treatment in both groups. Results: Mean BMI SDS at baseline was 0.08±0.60 in the normal weight group and 1.55±0.36 in the overweight/obesity group. Initial CA, BA, midparental height, and PAH were similar between the 2 groups. BA–CA after treatment was significantly decreased compared to baseline in both groups (P<0.001). Between the 2 groups, a decrease in BA–CA during treatment showed no significant difference. PAH at the end of treatment was significantly increased compared to baseline in both groups (P<0.001). PAH at the end of treatment in the overweight/obesity group (159.88±3.41 cm) was similar to that of the normal weight group (159.19±3.25 cm). Comparing the 2 groups according to change in BMI after treatment, there were no differences in ΔPAH, ΔBA–CA, and Δheight SDS for BA. Conclusion: GnRHa treatment in obese girls with CPP improved the height outcome and had similar results in normal weight CPP girls. Obesity might not affect the efficacy of GnRHa in girls with CPP.
참고문헌 (30)
- Parent AS, "The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration", Endocr Rev, 24, pp.668~693 (2003)
- Lee PA, "Central precocious puberty. An overview of diagnosis, treatment, and outcome", Endocrinol Metab Clin North Am, 28, pp.901~918 (1999)
- Partsch CJ, "Management and outcome of central precocious puberty", Clin Endocrinol (Oxf ), 56, pp.129~148 (2002)
- Lahlou N, "Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.723~737 (2000)
- 김은영, "Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty", Korean Journal of Pediatrics, 28(1), pp.1~7 (2015), 대한소아과학회
- Latronico AC, "Causes, diagnosis, and treatment of central precocious puberty", Lancet Diabetes Endocrinol, 4, pp.265~274 (2016)
- Arrigo T, "Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty", Eur J Endocrinol, 150, pp.533~537 (2004)
- De Bond JA, "Kisspeptin and energy balance in reproduction", Reproduction, 147, pp.R53~R63 (2014)
- 문진수, "2007 한국 소아 청소년 성장도표 : 개발 과정과 전망", Korean Journal of Pediatrics, 51(1), pp.1~25 (2008), 대한소아과학회
- Greulich W, "Radiologic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Bayley N, "Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
- Marshall WA, "Variations in pattern of pubertal changes in girls", Arch Dis Child, 44, pp.291~303 (1969)
- Tanner JM, "Standards for children's height at ages 2-9 years allowing for heights of parents", Arch Dis Child, 45, pp.755~762 (1970)
- Mogensen SS, "Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty", J Clin Endocrinol Metab, 96, pp.1393~1401 (2011)
- 김한결, "Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty", Annals of Laboratory Medicine, 31(4), pp.244~249 (2011), 대한진단검사의학회
- "The early detection of precocious puberty is important" (2013)[URL]
- Yang L, "Prevalence of overweight and obesity in the United States, 2007-2012", JAMA Intern Med, 175, pp.1412~1413 (2015)
- Ogden CL, "Prevalence of overweight and obesity in the United States, 1999-2004", JAMA, 295, pp.1549~1555 (2006)
- Heger S, "Impact of weight status on the onset and parameters of puberty: analysis of three representative cohorts from central Europe", J Pediatr Endocrinol Metab, 21, pp.865~877 (2008)
- He Q, "Bmi in childhood and its association with height gain, timing of puberty, and final height", Pediatr Res, 49, pp.244~251 (2001)
- 윤주영, "특발성 진성 성조숙증 여아에서 1년간의 성선자극호르몬 방출호르몬 효능약제 치료 전후 비만도의 관계", Annals of Pediatirc Endocrinology & Metabolism, 16(3), pp.165~171 (2011), 대한소아내분비학회
- Partsch CJ, "Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.747~758 (2000)
- Arrigo T, "Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty", Eur J Endocrinol, 141, pp.140~144 (1999)
- Gyon Y, "Age at menarche and near final height after treatment with gonadotropinreleasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty", Clin Pediatr Endocrinol, 24, pp.175~183 (2015)
- Heger S, "Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function", J Clin Endocrinol Metab, 84, pp.4583~4590 (1999)
- Shiasi Arani K, "Gonadotropin-releasing hormone agonist therapy and obesity in girls", Int J Endocrinol Metab, 13, pp.e23085~ (2015)
- Paterson WF, "Auxological outcome and time to menarche following longacting goserelin therapy in girls with central precocious or early puberty", Clin Endocrinol (Oxf), 61, pp.626~634 (2004)
- Wolters B, "Treatment with gonadotropinreleasing hormone analogues: different impact on body weight in normal-weight and overweight children", Horm Res Paediatr, 78, pp.304~311 (2012)
- Lee HS, "Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty", Endocrine, 54, pp.497~503 (2016)
- Pich J, "Weight selfregulation process in adolescence: the relationship between control weight attitudes, behaviors, and body weight status", Front Nutr, 2, pp.14~ (2015)